X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs SANOFI INDIA - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES SANOFI INDIA PIRAMAL ENTERPRISES/
SANOFI INDIA
 
P/E (TTM) x 8.7 34.0 25.7% View Chart
P/BV x 2.9 6.8 42.5% View Chart
Dividend Yield % 0.8 1.3 63.6%  

Financials

 PIRAMAL ENTERPRISES   SANOFI INDIA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
SANOFI INDIA
Dec-16
PIRAMAL ENTERPRISES/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs2,0954,560 45.9%   
Low Rs1,0254,400 23.3%   
Sales per share (Unadj.) Rs492.81,028.5 47.9%  
Earnings per share (Unadj.) Rs72.6129.0 56.3%  
Cash flow per share (Unadj.) Rs94.7186.0 50.9%  
Dividends per share (Unadj.) Rs21.0068.00 30.9%  
Dividend yield (eoy) %1.31.5 88.7%  
Book value per share (Unadj.) Rs862.5753.6 114.4%  
Shares outstanding (eoy) m172.5623.03 749.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.24.4 72.7%   
Avg P/E ratio x21.534.7 61.9%  
P/CF ratio (eoy) x16.524.1 68.4%  
Price / Book Value ratio x1.85.9 30.4%  
Dividend payout %28.952.7 54.9%   
Avg Mkt Cap Rs m269,194103,174 260.9%   
No. of employees `0004.03.6 110.8%   
Total wages/salary Rs m17,9393,592 499.4%   
Avg. sales/employee Rs Th21,190.36,537.7 324.1%   
Avg. wages/employee Rs Th4,470.1991.4 450.9%   
Avg. net profit/employee Rs Th3,120.0819.8 380.6%   
INCOME DATA
Net Sales Rs m85,03723,686 359.0%  
Other income Rs m2,338708 330.2%   
Total revenues Rs m87,37424,394 358.2%   
Gross profit Rs m34,9915,281 662.6%  
Depreciation Rs m3,8171,313 290.7%   
Interest Rs m20,31015 135,398.7%   
Profit before tax Rs m13,2024,661 283.2%   
Minority Interest Rs m1,6990-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,2811,691 134.9%   
Profit after tax Rs m12,5202,970 421.6%  
Gross profit margin %41.122.3 184.6%  
Effective tax rate %17.336.3 47.6%   
Net profit margin %14.712.5 117.4%  
BALANCE SHEET DATA
Current assets Rs m87,59015,673 558.9%   
Current liabilities Rs m185,5786,678 2,779.0%   
Net working cap to sales %-115.238.0 -303.4%  
Current ratio x0.52.3 20.1%  
Inventory Days Days3176 40.8%  
Debtors Days Days4822 213.1%  
Net fixed assets Rs m108,5238,098 1,340.1%   
Share capital Rs m345230 149.8%   
"Free" reserves Rs m148,48117,088 868.9%   
Net worth Rs m148,82617,356 857.5%   
Long term debt Rs m144,9570-   
Total assets Rs m482,39425,400 1,899.2%  
Interest coverage x1.7311.7 0.5%   
Debt to equity ratio x1.00-  
Sales to assets ratio x0.20.9 18.9%   
Return on assets %6.811.8 57.9%  
Return on equity %8.417.1 49.2%  
Return on capital %12.026.9 44.4%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m15,0017,145 209.9%   
Fx outflow Rs m5,1506,846 75.2%   
Net fx Rs m9,851299 3,294.6%   
CASH FLOW
From Operations Rs m-100,3933,226 -3,112.0%  
From Investments Rs m-24,202-1,555 1,556.4%  
From Financial Activity Rs m135,705-1,818 -7,464.5%  
Net Cashflow Rs m11,110-147 -7,557.6%  

Share Holding

Indian Promoters % 52.9 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 4.0 14.4 27.8%  
FIIs % 26.6 14.6 182.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 10.5 157.1%  
Shareholders   93,274 15,184 614.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   VENUS REMEDIES  ORCHID PHARMA LTD  GSK PHARMA  J.B.CHEMICALS  SHASUN PHARMA  

Compare PIRAMAL ENTERPRISES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Cuts Losses; TCS Up 3%(Closing)

After opening the day in red, share markets in India witnessed volatile trading activity throughout the day but clawed back some gains in the final hours of the trading window.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Jun 15, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 5-YR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS